If artificial intelligence were submitted to the FDA for approval, it would likely pass efficacy trials with impressive results.
In controlled environments, the gains are measurable. Professionals using generative AI tools complete certain tasks 37% faster and produce output rated 18% higher in quality, according to research from MIT Sloan. McKinsey reports that 65% of organizations now use generative AI regularly, nearly double the rate from the prior year. Goldman Sachs estimates AI could raise global GDP by 7% over the next decade.
Those numbers would clear most regulatory hurdles.
But every breakthrough drug comes with a label.
And the label is where the real story begins.
The Wegovy Precedent
When Wegovy was approved for chronic weight management, it marked a turning point in metabolic medicine. Clinical trials published in the New England Journal of Medicine showed average weight loss of approximately 14.9% over 68 weeks. For patients who had struggled for years, that outcome was transformative.
The market responded accordingly. Novo Nordisk’s valuation climbed dramatically as demand surged.
Yet the drug’s success did not eliminate its complexity. Gastrointestinal side effects were common. Discontinuation often led to weight regain if underlying behaviors were unchanged. The medication altered biological signals, but sustainable outcomes still depended on lifestyle integration.
The lesson was not that the drug failed.
The lesson was that efficacy is not the same as durability.
Artificial intelligence now stands at a similar inflection point.
From Productivity Gains To Systemic Risk
In early adoption phases, AI functions like a performance enhancer. It reduces friction in writing, coding, analysis, and customer service workflows. It can summarize thousands of documents in minutes. It can draft legal memos, generate financial models, and produce strategic briefs with startling fluency.
For executives under pressure to increase output without expanding headcount, the appeal is obvious.
But consider another statistic. Gartner estimates that at least 30% of generative AI projects will be abandoned after proof of concept by 2025, often due to poor data quality, unclear governance, escalating costs, or insufficient risk controls.
That figure is less about technical capability and more about organizational readiness.
In pharmaceutical terms, the drug performs in trials. It struggles in the real world.
The Metabolism Of An Organization
In medicine, weight-loss drugs can suppress appetite or alter hormonal pathways, creating rapid, measurable change. Exercise, by contrast, strengthens muscle fibers, improves insulin sensitivity, and enhances cardiovascular function. Both produce weight loss. Only one systematically builds resilience.
AI presents a comparable choice.
It can compensate for inefficiencies in thinking and workflow. It can produce clarity where teams previously experienced bottlenecks. But if an organization lacks disciplined decision rights, high-quality data governance, or cultural alignment, AI does not resolve those weaknesses.
It amplifies them.
A flawed dataset fed into an automated system generates error at scale. A misaligned leadership team empowered with faster tools accelerates misalignment. Automation without oversight increases velocity without necessarily improving direction.
Technology multiplies whatever foundation exists beneath it.
Cognitive Erosion And The Illusion Of Competence
One of the more subtle concerns emerging in academic research involves human judgment. Studies from Harvard Business School and the Wharton School suggest that heavy reliance on algorithmic recommendations can reduce exploratory thinking and independent evaluation over time. When machine outputs appear authoritative, individuals are more likely to defer to them, even when uncertainty remains.
This is not a failure of intelligence. It is a function of cognitive bias. Humans are predisposed to trust systems that present structured, confident responses.
Large language models generate probabilistic text based on pattern recognition. They do not reason as humans do. Yet the coherence of their language creates a perception of certainty.
Confidence increases.
Validation often does not.
In high-stakes environments such as healthcare, finance, or infrastructure, that imbalance introduces material risk.
The Marketing Narrative Versus Operational Reality
Like pharmaceutical advertising, the public narrative around AI emphasizes transformation. Automate workflows. Replace repetitive labor. Unlock exponential productivity. Capture competitive advantage.
The operational reality is more complex. Data must be structured and secure. Compliance requirements must evolve. Bias mitigation must be deliberate. Cybersecurity exposure increases with system interconnectivity. Regulatory scrutiny is intensifying across the United States and Europe.
Stanford’s AI Index has documented a sharp increase in AI-related incidents, including misuse and data leakage. The issue is not that AI is inherently unsafe. It is that scale amplifies both strengths and weaknesses.
The side effects are manageable.
But they are real.
The Strategic Question
If artificial intelligence were prescribed as a treatment, responsible use would likely require companion practices: rigorous data hygiene, defined governance structures, transparent decision criteria, and human oversight.
In other words, AI functions best as a supplement.
It does not replace leadership maturity.
The most sophisticated organizations are not racing to implement AI indiscriminately. They are investing in validation frameworks, decision architecture, and cultural readiness before expanding automation. They understand that speed without alignment can be more expensive than slowness.
In capital markets, leverage magnifies returns and risk simultaneously. AI operates in similar fashion. It is leverage applied to cognition and process.
The question is not whether to use it.
The question is whether the enterprise can metabolize it responsibly.
A Final Consideration
Every transformative technology introduces asymmetry. Those who integrate it wisely gain disproportionate advantage. Those who integrate it prematurely inherit disproportionate exposure.
Artificial intelligence is not a cure for organizational dysfunction. It is an accelerant.
In disciplined environments, it enhances capability. In fragmented environments, it accelerates fragility.
If AI were a pill, the approval would likely be unanimous.
The label, however, would be long.
And the most prudent leaders would read it carefully.
